Malaysia’s biotechnology and wellness landscape has taken a significant leap forward with the soft launch of two innovative health products: Dr. Kengo’s Euglena Royal Algae Drink and Euglena Collagen Shot. These products are the result of a strategic collaboration between local biotechnology firm Sirehemas Pharma Sdn. Bhd. and renowned Japanese biotech company Euglena Co., Ltd., with facilitation and support by the Malaysian Technology Development Corporation (MTDC).
The launch, held at Menara MATRADE, Kuala Lumpur, was attended by representatives from MATRADE, MTDC, and SME Bank, reflecting strong institutional support for innovation-led development and export-focused initiatives.
This collaboration represents more than a new product debut—it is a critical step in Malaysia’s journey to becoming a regional hub for science-based wellness solutions and high-value biotechnology products. The products, developed using the microalga Euglena, are positioned to support daily vitality, natural immunity, and beauty. With 59 essential nutrients and a powerful bioactive compound known as paramylon, Euglena has been scientifically validated to promote health in a natural and sustainable way.
“At Sirehemas Pharma, we believe in the power of science, the importance of natural solutions, and the strength of collaboration,” said Puan Nik Juzailah, representing Sirehemas. “In Euglena Co., Ltd., we found a partner who not only shares these values but brings decades of research and a global commitment to innovation.”
According to Puan Nik, the early connection between the two companies was made possible through MTDC’s efforts in bridging high-potential Malaysian SMEs with global tech partners. “This is a prime example of how technology development agencies can serve as catalysts for high-impact collaborations,” she added.
The newly launched products are:
- Euglena Royal Algae Drink – designed to support daily energy, overall wellness, and vitality using Euglena’s nutrient-rich profile.
- Euglena Collagen Shot – a premium blend that combines Euglena with high-quality marine collagen to promote skin health and beauty.
The products also align with a broader government push to promote wellness, biotech innovation, and sustainability. The 2024 National Budget, for example, allocated RM20 million to establish Malaysia’s first AI faculty at Universiti Teknologi Malaysia—underscoring the government’s drive to strengthen the nation’s digital and scientific capabilities.
Sirehemas Pharma plans to scale both products for export, starting with ASEAN and Japan, with long-term aspirations to penetrate global markets. The company continues to work closely with industry stakeholders, government agencies, and research institutions to ensure product efficacy, safety, and competitiveness.
“This launch is more than a business milestone,” said Puan Nik. “It’s about placing Malaysia on the map as a serious player in sustainable wellness innovation driven by science and collaboration.”
The Malaysian robotics and biotech sectors have been identified as key contributors to future GDP growth, with projections from the Ministry of Science, Technology and Innovation (MOSTI) indicating a market value of RM103.1 billion by 2030 for robotics alone. Sirehemas’s work adds to this momentum by integrating advanced biosciences with local entrepreneurship and international expertise.
Looking ahead, the company remains focused on innovation, job creation, and its mission to contribute meaningfully to the health and wellbeing of communities—both locally and globally.
“With the support of agencies like MTDC, and strong bilateral ties with countries like Japan, we are building a foundation for a future where Malaysia becomes a global reference point for biotech-driven wellness,” Puan Nik concluded.